3034-31-9|N-Phenyl isonicotinicamide| Ambeed

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 3034-31-9 ] Purity: 97% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 3034-31-9 ]

CAS No. :	3034-31-9
Formula :	C₁₂H₁₀N₂O
M.W :	198.22
SMILES Code :	O=C(NC1=CC=CC=C1)C2=CC=NC=C2
MDL No. :	MFCD00459246
InChI Key :	FCTZHFATVFONMW-UHFFFAOYSA-N
Pubchem ID :	220840

Safety of [ 3034-31-9 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302
Precautionary Statements:	P280-P305+P351+P338

Computational Chemistry of [ 3034-31-9 ] Show Less

Physicochemical Properties

Num. heavy atoms	15
Num. arom. heavy atoms	12
Fraction Csp3	0.0
Num. rotatable bonds	3
Num. H-bond acceptors	2.0
Num. H-bond donors	1.0
Molar Refractivity	58.45
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	41.99 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	1.66
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	1.55
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	2.14
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	1.47
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	2.07
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	1.78

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-2.44
Solubility	0.721 mg/ml ; 0.00364 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-2.04
Solubility	1.8 mg/ml ; 0.00909 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-4.55
Solubility	0.00564 mg/ml ; 0.0000284 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Moderately soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	Yes
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	Yes
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-6.41 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	1.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	0.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	1.3

Application In Synthesis of [ 3034-31-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 3034-31-9 ]
Downstream synthetic route of [ 3034-31-9 ]

[ 3034-31-9 ] Synthesis Path-Upstream 1~1

1
[ 3034-31-9 ]
[ 80194-83-8 ]

References: [1] Tetrahedron, 1989, vol. 45, # 23, p. 7469 - 7476.

[ 3034-31-9 ] Synthesis Path-Downstream 1~36

1
[ 55-22-1 ]
[ 62-53-3 ]
[ 3034-31-9 ]

Yield	Reaction Conditions	Operation in experiment
99%		A solution of isonicotinic acid (14, 5.0 g, 40.6 mmol) in thionyl chloride (40 mL) was heated at reflux for 2 h. After completion of the reaction, thionyl chloride was removed under reduced pressure. THF (50 mL), K2CO3 (16.8 g, 121.9 mmol) and aniline (3.78 g, 40.6 mmol) were added to the residue and the reaction mixture was stirred at room temperature for 24 h. The reaction mixture was diluted with water (100 mL) and extracted with EtOAc (2 x 100 mL). The combined organic layer was concentrated and the residue was recrystallized from EtOAc-hexanes (60:40) to afford the product 15 (8.0 g, 99%) as a light yellow solid: mp 166-168 C. IR (KBr) 1344, 1653, 1465, 665 cm 1; *H NMR (DMSO-ifc, 300 MHz) δ 10.49 (s, 1 H), 8.78 (m, 2 H), 7.86 (m, 2 H), 7.78 (m, 2 H), 7.39 (t, = 8.0 Hz, 2 H), 7.15 (t, = 6.5 Hz, 1 H).

References: [1]Patent: WO2017/160898,2017,A1 .Location in patent: Paragraph 00105; 00125.
[2]Organic and Biomolecular Chemistry,2019,vol. 17,p. 4087 - 4101.
[3]Journal of Medicinal Chemistry,2021,vol. 64,p. 17146 - 17183.
[4]Journal of Medicinal Chemistry,2016,vol. 59,p. 1370 - 1387.
[5]Bioorganic and Medicinal Chemistry,2008,vol. 16,p. 6027 - 6033.
[6]Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry,1981,vol. 20,p. 1007 - 1008.

2
[ 3034-31-9 ]
[ 33513-42-7 ]
[ 156638-77-6 ]

Yield	Reaction Conditions	Operation in experiment
67%		A 2.5 M n-BuLi solution in hexanes (17.8 mL, 44.4 mmol) was added to a solution of 15 (4.0 g, 20 mmol) in dry THF (120 mL) at -78 C. The solution was held at -78 C for 0.5 h and then allowed to rise to 0 C and kept at 0 C for 6 min. The mixture was cooled to -78 C and DMF (2.94 mL, 40.4 mmol) was added. After 1 h at -78 C, the reaction mixture was warmed to 0 C and kept at 0 C for 1 h. H20 (40 mL) was added, the organic layer was separated, and the water layer was extracted with CHCI3 (2 x 40 mL). The combined organic layer was dried over Na2S04, concentrated, and purified by silica gel flash column chromatography (60:40 EtOAc- hexanes) to afford compound 16 (3.0 g, 67%) as an off-white solid: mp 209-211 C. IR (KBr) 3356, 1721, 776 cm ; lH NMR (DMSC fc, 300 MHz) δ 8.97 (s, 1 H), 8.86 (d, = 4.9 Hz, 1 H), 7.77 (m, 3 H), 7.48 (t, = 6.1 Hz, 2 H), 7.28 (t, = 7.5 Hz, 1 H), 7.10 (br s, 1 H), 6.69 (s, 1 H).

References: [1]Journal of Medicinal Chemistry,2021,vol. 64,p. 17146 - 17183.
[2]Journal of Medicinal Chemistry,2016,vol. 59,p. 3840 - 3853.
[3]Patent: WO2017/160898,2017,A1 .Location in patent: Paragraph 00105; 00126.
[4]Synthetic Communications,1994,vol. 24,p. 1789 - 1798.
[5]Synthesis,1996,p. 1212 - 1216.
[6]Journal of Medicinal Chemistry,2016,vol. 59,p. 1370 - 1387.

3
[ 3034-31-9 ]
[ 74-88-4 ]
[ 81795-19-9 ]

References: [1]Tetrahedron,1981,vol. 37,p. 4185 - 4188.
[2]Journal of biochemical toxicology,1996,vol. 11,p. 33 - 43.

4
[ 3034-31-9 ]
[ 73415-85-7 ]

Yield	Reaction Conditions	Operation in experiment
	In chloroform; acetic acid;	PREPARATION A Preparation of 4-(N-phenylcarbamoyl)piperidine 4-(N-phenylcarbamoyl)pyridine [75.0 g, prepared as in Chem. Abs., 2013h (1958)] was hydrogenated in acetic acid (800 ml) using a platinum oxide catalyst at 50 p.s.i./30. The catalyst was then removed by filtration, the solution evaporated, the residue basified to about pH 12 with sodium hydroxide, extracted with chloroform, and the organic extract discarded. The aqueous phase was evaporated to dryness, the residue boiled with chloroform, filtered and evaporated to leave 4-(N-phenylcarbamoyl)piperidine (17.0 g), m.p. 121-127. The hydrochloride salt, m.p. 231-233, was prepared in isopropanol from the free base and hydrogen chloride, and was recrystallized from isopropanol/ethyl acetate. Analysis %: Found: C, 60.1; H, 7.2; N, 11.7. Calculated for C12 H16 N2 O.HCl: C, 59.9; H, 7.1; N, 11.6.

References: [1]Journal of Organic Chemistry,1986,vol. 51,p. 513 - 517.
[2]Patent: US4243666,1981,A .

5
[ 3034-31-9 ]
[ 89565-24-2 ]

References: [1]Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry,1983,vol. 22,p. 1029 - 1043.

6
[ 3034-31-9 ]
[ 14178-44-0 ]

References: [1]Tetrahedron,1989,vol. 45,p. 7469 - 7476.

7
[ 3034-31-9 ]
[ 17159-79-4 ]
C₁₅H₁₇NO₄ [ No CAS ]
C₁₅H₁₇NO₄ [ No CAS ]

References: [1]Journal of Organic Chemistry,2005,vol. 70,p. 9222 - 9229.

8
[ 3034-31-9 ]
C₁₇H₂₁NO₄ [ No CAS ]

References: [1]Journal of Organic Chemistry,2005,vol. 70,p. 9222 - 9229.
[2]Journal of Organic Chemistry,2005,vol. 70,p. 9222 - 9229.
[3]Journal of Organic Chemistry,2005,vol. 70,p. 9222 - 9229.

9
[ 3034-31-9 ]
N,N-dimethyl 2-phenylimino-2-(4-pyridyl)ethanamide [ No CAS ]

References: [1]Journal of Organic Chemistry,2005,vol. 70,p. 5344 - 5346.

10
[ 55-22-1 ]
[ 3034-31-9 ]

References: [1]Journal of Organic Chemistry,1999,vol. 64,p. 8546 - 8556.
[2]Pharmaceutical Chemistry Journal,1998,vol. 32,p. 597 - 599.
[3]Tetrahedron,1989,vol. 45,p. 7469 - 7476.
[4]Organic Letters,2014,vol. 16,p. 3142 - 3145.
[5]Journal of Medicinal Chemistry,2016,vol. 59,p. 3840 - 3853.

11
[ 3034-31-9 ]
2-Phenyl-isothiazolo[5,4-c]pyridin-3-one [ No CAS ]

References: [1]Journal of Medicinal Chemistry,1994,vol. 37,p. 3071 - 3078.

12
[ 3034-31-9 ]
N-Phenyl-3-phenylmethanesulfinyl-isonicotinamide [ No CAS ]

References: [1]Journal of Medicinal Chemistry,1994,vol. 37,p. 3071 - 3078.

13
[ 3034-31-9 ]
[ 100-39-0 ]
1-benzyl-1,2,3,6-tetrahydropyridinyl-4-carboxylic acid phenylamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With sodium borohydrid; In ethanol; N,N-dimethyl-formamide;	Step 1: 1-Benzyl-1,2,3,6-tetrahydropyridinyl-4-carboxylic acid phenylamide A mixture of <strong>[3034-31-9]pyridine-4-carboxylic acid phenylamide</strong> (3.96 g, 20 mmol), benzyl bromide (3.76 g, 22 mmol) and DMF (10 ml) was stirred at 105 C. for 15 h and the resulting solid mass, on cooling, suspended in ethanol (40 ml). Sodium borohydride (0.95 g, 25 mmol) was added in portions and the suspension stirred for 3 h, after which it was filtered, the filtrate evaporated, and the residue partitioned between water (100 ml) and ethyl acetate (275 ml). The organic layers were extracted with HCl (1M: 350 ml), the combined extracts basified with aqueous sodium hydroxide, and the suspension re-extracted with dichloromethane (2*50 ml). After drying (MgSO4), the dichloromethane layers were evaporated to leave the product as a yellow gum (4.58 g). δH (CDCl3) 2.52 (2H, br s, tetrahydropyridinyl CH2), 2.68 (2H, t, J 5.7 Hz, tetrahydropyridinyl CH2), 3.17 (2H, dd, J 6.0, 2.7 Hz, tetrahydropyridinyl CH2), 3.64 (2H, s, PhCH2 N), 6.62 (1H, dd, J 3.3, 1.8 Hz, CR=CH), 7.10 (1H, t, J 7.3 Hz, ArH), 7.26-7.48 (7H, m, ArH) and 7.53 (2H, d, J 7.6 Hz, ArH).

References: [1]Patent: US5563152,1996,A .

14
[ 75-21-8 ]
[ 3034-31-9 ]
[ 185144-25-6 ]

Yield	Reaction Conditions	Operation in experiment
43%	With n-butyllithium; In tetrahydrofuran; 1,4-dioxane; methanol;	Step 1 3-(2-Hydroxyethyl)-<strong>[3034-31-9]N-phenylisonicotinamide</strong> To a solution of <strong>[3034-31-9]N-phenylisonicotinamide</strong> (1.98 g, 10 mmol) in tetrahydrofuran (40 ml) at -78 C. was added a solution of n-butyllithium (1.6M in hexanes; 13.5 ml, 21.6 mmol) and the resulting red solution stirrred for 40 minutes before addition of a solution of ethylene oxide in dioxane (3.56M; 3.0 ml, 11 mmol). After allowing the mixture to warm to room temperature over 21/2 hours, the reaction was quenched by addition of methanol (8 ml). The solvent was evaporated and the residue partitioned between ethyl acetate (70 ml) and water (25 ml). The organic layer was washed with saturated brine (25 ml), dried (MgSO4) and evaporated. The residue was chromatographed on silica eluding with 10% methanol/dichloromethane to afford the title compound as a solid (1.05 g, 43%); δH (CDCl3) 3.07 (2H, t, J 5.6 Hz, ArCH2 CH2 OH), 3.70 (1H, br s, OH), 4.10 (2H, t, J 5.6 Hz, ArCH2 CH2 OH), 7.15-7.19 (1H, m, ArH), 7.35-7.39 (2H, m, ArH), 7.49 (1H, d, J 5.2 Hz, ArH), 7.69-7.71 (2H, m, ArH), 8.44-8.48 (2H, m, ArH), 9.77 (1H, s, NH).

References: [1]Patent: US5700941,1997,A .

15
[ 67-56-1 ]
[ 3034-31-9 ]
silver nitrate [ No CAS ]
trans-bis(N-phenylisonicotinamide)silver(I) nitrate - methanol (1:2) [ No CAS ]

References: [1]Chemical Communications,2007,p. 1433 - 1435.

16
[ 3034-31-9 ]
[ 4101-68-2 ]
1,1'-(1,10-decanediyl)bis[4-[(phenylamino)carbonyl]pyridinium bromide] [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry,2008,vol. 16,p. 6027 - 6033.

17
[ 3612-20-2 ]
[ 3034-31-9 ]
[ 1017599-00-6 ]

Yield	Reaction Conditions	Operation in experiment
		Reference Example 4-28 Production of 1'-benzyl-1H-spiro[furo[3,4-c]pyridine-3,4'-piperidin]-1-one At -78C, a hexane solution (500 mL) of 2.71 M n-butyllithium was dropwise added to a THF solution (4.00 L) of<strong>[3034-31-9]N-phenyl-4-pyridinecarboxamide</strong> (131 g). After stirred for 2.5 hours, a THF solution (650 mL) of 1-benzyl-4-piperidone (125 g) was dropwise added to it at -78C, and stirred for 1 hour. After warmed up to -20C, aqueous 1 N sodium hydroxide solution (1.00 L) was added to it, and concentrated under reduced pressure. After extracted with ethyl acetate, the aqueous layer was made acidic (pH ~1) by adding concentrated hydrochloric acid. After stirred for 1 hour, this was neutralized (pH ~8) with aqueous 12 % potassium carbonate solution. The precipitated solid was collected through filtration, washed with water, and dissolved in chloroform. This was washed with aqueous saturated sodium hydrogencarbonate solution, and dried with anhydrous sodium sulfate. The organic layer was concentrated under reduced pressure to obtain the entitled compound (152 g) as a white solid. ESI-MS Found: m/z 295[M+H]+

References: [1]Patent: EP2072519,2009,A1 .Location in patent: Page/Page column 41.

18
[ 3034-31-9 ]
[ 73415-54-0 ]

References: [1]Tetrahedron,2009,vol. 65,p. 8538 - 8541.

19
[ 3034-31-9 ]
[ 17159-79-4 ]
C₁₃H₁₅NO₅ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		The ISONICOTINAMIDE 1-1 (100 g, 0.50 mol, Kingchem), THF (0.5 L) and a 1 M LiBr solution (prepared by dissolving 1.50 mol of LiBr in 1.5 L of THF) were mixed in a flask. The resulting solution was degassed with nitrogen and cooled TO-65 C. n-BuLi (1.56 M in hexane; 666 ML, 1.04 mol) was then added while maintaining the batch temperature BELOW-55 C. The resulting solution was then aged at a temperature less THAN-55 C for a period between 1 to 7 hours to give a metalated anilide mixture. A solution of ethyl 4-oxocyclohexanecarboxylate 1-2 (100 mL, 0.63 mol, EMS Dottikon AG) in THF (1 L) was cooled in a separate flask to a temperature BELOW-60 C. To the solution was added the above metalated anilide mixture, while maintaining the batch temperature below-55 C. The resulting solution was aged at a temperature BELOW-55 C for 1 hour and then carefully quenched into H20 (1 L). The resulting mixture was warmed to 40 C and aged at 40 C for a period between 1 to 4 hours. After cooling to room temperature, the organic layer was removed and the aqueous layer (1.3 L; pH - 11) was washed with THF (1 L) to give an aqueous solution of the diacid 1-3.

References: [1]Patent: WO2004/104009,2004,A1 .Location in patent: Page 30-31.

20
[ 3034-31-9 ]
[ 106-38-7 ]
[ 1220349-01-8 ]
[ 1220349-08-5 ]

References: [1]Angewandte Chemie - International Edition,2010,vol. 49,p. 1275 - 1277.

21
[ 4746-97-8 ]
[ 3034-31-9 ]
[ 328233-20-1 ]

References: [1]Organic Process Research and Development,2010,vol. 14,p. 1269 - 1271.

22
[ 3034-31-9 ]
[ 501-65-5 ]
[ 1329663-53-7 ]

References: [1]Journal of Organic Chemistry,2011,vol. 76,p. 7583 - 7589.

23
[ 1570-45-2 ]
[ 62-53-3 ]
[ 3034-31-9 ]

References: [1]Synthesis,2012,vol. 44,p. 42 - 50.
[2]Research on Chemical Intermediates,2012,vol. 38,p. 1961 - 1968.

24
[ 14548-46-0 ]
[ 3034-31-9 ]

References: [1]Journal of Sulfur Chemistry,2011,vol. 32,p. 463 - 473.

25
[ 3034-31-9 ]
[ 2680-03-7 ]
[ 1389293-09-7 ]